Skip to Content
DAEWOONG PHARMACEUTICAL CO.LTD.
View All Menu
KR
EN
About Daewoong
About Daewoong
Our Purpose
CEO Message
Affiliates
Global Network
Company Culture
History
Ethics
Compliance Program
CEO Message
CP Rating
CP Activities
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing
Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics
Chemicals
Newsroom
Press Release
PR Videos
Investors
Overview
Corporate Governance
Overview
Board of Directors
Stockholder Info
Stockholder's meeting
Annual Reports
Balance Sheet
Income Statement
Credit Rating
Stock Info
Stock Info
Stock Status
IR
Events & Presentations
Earnings announcement
FAQ
Careers
Close All Menu
IR
Events & Presentations
Earnings announcement
IR Letter
IR Letter
2
Daewoong Pharmaceutical Reports Third Quarter 2023 Financial Results
2023-11-03
File Download
1
Nuceiva™(Botulinum toxin product) Approval in Europe
2020-03-09
File Download
이전 페이지
현재페이지
1
전체페이지
/ 1
다음 페이지
Search
search word
Delete
Search